195 related articles for article (PubMed ID: 32191807)
1. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
[TBL] [Abstract][Full Text] [Related]
2. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.
Yang P; Liu SZ; Li CY; Zhang WL; Wang J; Chen YT; Li S; Liu CL; Liu H; Cai QQ; Zhang W; Jing HM
Ann Hematol; 2024 Jan; ():. PubMed ID: 38165416
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract][Full Text] [Related]
4. Progress in molecular feature of smoldering mantle cell lymphoma.
Jiang P; Desai A; Ye H
Exp Hematol Oncol; 2021 Jul; 10(1):41. PubMed ID: 34256839
[TBL] [Abstract][Full Text] [Related]
5. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.
Pararajalingam P; Coyle KM; Arthur SE; Thomas N; Alcaide M; Meissner B; Boyle M; Qureshi Q; Grande BM; Rushton C; Slack GW; Mungall AJ; Tam CS; Agarwal R; Dawson SJ; Lenz G; Balasubramanian S; Gascoyne RD; Steidl C; Connors J; Villa D; Audas TE; Marra MA; Johnson NA; Scott DW; Morin RD
Blood; 2020 Jul; 136(5):572-584. PubMed ID: 32160292
[TBL] [Abstract][Full Text] [Related]
6. Blastoid Mantle Cell Lymphoma Presenting as an Oropharyngeal Mass.
Macapagal S; Wannaphut C; Takahashi T; Yinadsawaphan T; Nishimura Y; Acoba J
Cureus; 2024 Mar; 16(3):e56378. PubMed ID: 38633973
[TBL] [Abstract][Full Text] [Related]
7. Testicular involvement in mantle cell lymphoma: An analysis of 16 patients.
Alkhalili S; Manogna D; Safah H; Ellent E; Beversdorf W; Arora R; Saba NS
Leuk Res Rep; 2023; 20():100397. PubMed ID: 38053743
[TBL] [Abstract][Full Text] [Related]
8. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
10. Blastoid Mantle Cell Lymphoma.
Jain P; Wang M
Hematol Oncol Clin North Am; 2020 Oct; 34(5):941-956. PubMed ID: 32861288
[TBL] [Abstract][Full Text] [Related]
11. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
12. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
[TBL] [Abstract][Full Text] [Related]
14. "Triple hit" SOX11
Jain P; Tang G; Li S; Wang M
Am J Hematol; 2021 Jan; 96(1):165-166. PubMed ID: 32356355
[No Abstract] [Full Text] [Related]
15. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
Obr A; Klener P; Furst T; Kriegova E; Zemanova Z; Urbankova H; Jirkuvova A; Petrackova A; Malarikova D; Forsterova K; Cudova B; Sedlarikova L; Berkova A; Kasalova N; Papajik T; Trneny M
Br J Haematol; 2020 Dec; 191(5):e103-e106. PubMed ID: 32862455
[No Abstract] [Full Text] [Related]
16. High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.
Jain P; Dreyling M; Seymour JF; Wang M
J Clin Oncol; 2020 Dec; 38(36):4302-4316. PubMed ID: 33074750
[No Abstract] [Full Text] [Related]
17.
Wang L; Tang G; Medeiros LJ; Xu J; Huang W; Yin CC; Wang M; Jain P; Lin P; Li S
Haematologica; 2021 May; 106(5):1381-1389. PubMed ID: 32273477
[TBL] [Abstract][Full Text] [Related]
18. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Jung D; Jain P; Yao Y; Wang M
J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
[TBL] [Abstract][Full Text] [Related]
19. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
